Source link : https://www.newshealth.biz/health-news/immunotherapy-timing-in-early-stage-nsclc/
Do patients with early-stage non–small cell lung cancer (NSCLC) benefit from continuing immunotherapy beyond surgery? The short answer: Oncologists don’t know for sure. Since October 2023, the US Food and Drug Administration (FDA) has approved three checkpoint inhibitors — pembrolizumab (Keytruda), durvalumab (Imfinzi), and most recently nivolumab (Opdivo) — alongside platinum-containing chemotherapy before surgery and […]
Author : News Health
Publish date : 2024-12-23 06:16:19
Copyright for syndicated content belongs to the linked Source.